Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd., a leader in affordable and innovative medicines, celebrates 40 years of patient service with strong financial results for FY24, including record revenues and profits. The company’s growth has been particularly robust in the U.S. market, with significant advancements in licensing and collaborations to build their future pipeline. A commitment to sustainability and increasing global patient access remains core to Dr. Reddy’s strategy moving forward.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
